Mehmet Gokhan Gonenli

Mehmet Gokhan Gonenli

Auto-generated profile, based on publicly available information

Mehmet Gokhan Gonenli

Department of Psychiatric Nursing, Koç University School of Nursing, İstanbul, Türkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
MZMujdat Zeybel
Mujdat Zeybel
OAOzlem Altay
Ozlem Altay
Muhammad ArifMuhammad Arif
Muhammad Arif
XLXiangyu Li
Xiangyu Li
HYHong Yang
Hong Yang
AMAdil Mardinoglu
Adil Mardinoglu
Nonalcoholic fatty liver disease (NAFLD) refers to excess fat accumulation in the liver. In animal experiments and human kinetic study, we found that administration of combined metabolic activators (CMAs) promotes the oxidation of fat, attenuates the resulting oxidative stress, activates mitochondria, and eventually removes excess fat from the liver. Here, we tested the safety and efficacy of CMA in NAFLD patients in a placebo‐controlled 10‐week study. We found that CMA significantly decreased hepatic steatosis and levels of aspartate aminotransferase, alanine aminotransferase, uric acid, and creatinine, whereas found no differences on these variables in the placebo group after adjustment for weight loss. By integrating clinical data with plasma metabolomics and inflammatory proteomics as well as oral and gut metagenomic data, we revealed the underlying molecular mechanisms associated with the reduced hepatic fat and inflammation in NAFLD patients and identified the key players involved in the host–microbiome interactions. In conclusion, we showed that CMA can be used to develop a pharmacological treatment strategy in NAFLD patients.

1 January 2021 in Northern Clinics of Istanbul
Verified
Journal Article
Open access
HSHavva Sezer
Havva Sezer
DYDilek Yazici
Dilek Yazici
HCHande Bulut Canbaz
Hande Bulut Canbaz
BBBahar Bekdemir
Bahar Bekdemir
MGMehmet Gokhan Gonenli
Mehmet Gokhan Gonenli
ENEmine Ayca Nalbantoglu
Emine Ayca Nalbantoglu
OBJECTIVE: It is thought that there is not enough data about the frequency of acceptance of oral glucose tolerance test (OGTT) in Turkish pregnant women. The aim of this study was to investigate the frequency of acceptance of OGTT among participants in our single tertiary center. METHODS: The data of non-diabetic 344 pregnant women seen at the Obstetrics Clinic of our hospital between September 2016 and September 2017 were obtained from the hospital records. Women who did not have regular follow-up during pregnancy were excluded. One of the two or one-step approaches was used in the diagnosis of gestational diabetes mellitus (GDM) depending on the choice of the physician following the patient. RESULTS: There were 223 subjects eligible for the study. One hundred seventy-seven pregnant women (79.4%) accepted to do OGTT. We determined that 46 women (20.6%) did not complete at least one OGTT, of whom 74% (n=34) never completed the recommended screening test in this cohort. The overall frequency of GDM was approximately 15.2% (n=34). OGTT acceptability was higher among pregnant women with university graduates (p=0.02). Adverse pregnancy outcomes were similar between the accepted and rejected groups. Among the reasons for OGTT rejection, the media had a significant influence (n=35). CONCLUSION: Our results show that a significant percentage of patients refused to do OGTT. Therefore the actual frequency of pregnant women with GDM could not be determined. One way to increase compliance may be recommending only the one-step test for pregnant women in countries with a high rejection rate of OGTT.

1 January 2021 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
PDF file
MGMehmet Gökhan Gönenli
Mehmet Gökhan Gönenli
ZKZeynep Komesli
Zeynep Komesli
SISaid İnCir
Said İnCir
ÖYÖzlem Yalçın
Özlem Yalçın
OAOlga Meltem Akay
Olga Meltem Akay
Identifying a hypercoagulable state in patients with COVID-19 may help identify those at risk for virus–induced thromboembolic events and improve clinical outcomes using personalized therapeutic approaches. Herein, we aimed to perform a global assessment of the patients’ hemostatic system with COVID-19 using rotational thromboelastometry (ROTEM) and to describe whether patients with different disease severities present different coagulation profiles. Together with 37 healthy volunteers, a total of 65 patients were included and then classified as having mild, moderate, and severe disease depending on clinical severity. Peripheral blood samples were collected and analyzed using a ROTEM Coagulation Analyzer. Also, complete blood count and coagulation parameters including prothrombin time, activated partial thromboplastin time, fibrinogen levels, and D-dimer levels were measured at admission. EXTEM and INTEM MCF (P < 0.001) values were significantly higher and the EXTEM CFT (P = 0.002) value was significantly lower in patients with COVID-19 when compared with controls. In particular, patients with the severe disease showed a significant decrease in CFT (P < 0.001) and an increase in MCF (P < 0.001) in both INTEM and EXTEM assays compared with patients with the non-severe disease. Correlation analysis revealed significant correlations between ROTEM parameters and other coagulation parameters. There were significant positive correlations between fibrinogen, D-dimer, platelet count, and MCF in both EXTEM and INTEM assays. Our data demonstrate thromboelastographic signs of hypercoagulability in patients with COVID-19, which is more pronounced in patients with increased disease severity. Therefore, ROTEM analysis can classify subsets of patients with COVID-19 at significant thrombotic risk and assist in clinical decisions.

17 November 2021 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
MGMehmet Gökhan Gönenli
Mehmet Gökhan Gönenli
SKSema Kaymaz‐Tahra
Sema Kaymaz‐Tahra
MKMete Kara
Mete Kara
GKGökhan Keser
Gökhan Keser
AYAyten Yazıcı
Ayten Yazıcı
NANilüfer Alpay‐Kanıtez
Nilüfer Alpay‐Kanıtez

21 December 2022 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
MGMehmet Gokhan Gonenli
Mehmet Gokhan Gonenli
IKIlker Kayi
Ilker Kayi
NANilufer Alpay-Kanitez
Nilufer Alpay-Kanitez
TBTuba Baydaş
Tuba Baydaş
MKMurat Kose
Murat Kose
Onder ErgonulOnder Ergonul
Onder Ergonul
Objective: Throughout the pandemic, physicians working at the frontlines have embarked on various quests to protect themselves, and many physicians preferred using hydroxychloroquine (HQN) as a prophylactic agent. This study aimed to investigate the reasons leading physicians to use HQN and its effects on them. Materials and Methods: This study is cross-sectional with a target population of physicians working in pandemic hospitals in İstanbul, Turkey. We invited participants from seven hospitals via email between May 14 and June 13, 2020. An online questionnaire, including 57 questions, was sent to physicians. Results: A total of 148 (26%) physicians out of 564 participants had used hydroxychloroquine for prevention. Older physicians and those with a history of exposure to COVID-19 patients without protection used prophylactic HQN more frequently. The use of HQN did not differ statistically in terms of being infected among the exposed physicians (p=0.52). Nineteen (13%) physicians using HQN developed side effects related to the drug. Diarrhea and nausea were the most common. Conclusion: Prophylactic HQN use was more common among physicians older than 40 years and with higher exposure rates to a COVID-19 patient without protection. The physicians working on the front line had the highest rate of infection. HQN was not effective in the prophylaxis of COVID-19 among the exposed physicians. Keywords: COVID-19, hydroxychloroquine, prophylaxis, physicians

11 February 2026 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
MGMehmet Gokhan Gonenli
Mehmet Gokhan Gonenli
BMBerkay Muslu
Berkay Muslu
OBOsman Faruk Bayramlar
Osman Faruk Bayramlar
ADAhmet Demirel
Ahmet Demirel
YTYavuz Burak Tor
Yavuz Burak Tor
TATimur Selcuk Akpinar
Timur Selcuk Akpinar
To describe etiologies of classic fever of unknown origin (FUO) and evaluate associations of FDG PET/CT, C-reactive protein (CRP), age, and Charlson Comorbidity Index (CCI) with biopsy performance, diagnostic yield, and time to diagnosis. Retrospective cohort of 179 adults with classic FUO. In the PET/CT subgroup (n = 106), logistic regression assessed predictors of biopsy and final diagnosis; CRP discrimination was evaluated by ROC analysis; and time to diagnosis by Kaplan-Meier analysis (CCI=0 vs CCI≥3). Autoimmune/autoinflammatory diseases (31.3%), infections (30.7%), and malignancy (19.0%) predominated; 16.8% remained undiagnosed. PET/CT positivity predicted biopsy (aOR 4.85, 95% CI: 1.45-16.19) but not diagnostic yield. Higher log-CRP increased odds of diagnosis (OR 2.11, 95% CI: 1.28-3.48), whereas age decreased odds (OR 0.95 per year, 95% CI: 0.90-0.99). CRP AUC 0.68 (cut-off 30.3 mg/L). CCI≥3 was associated with longer time to diagnosis (log-rank P = 0.034). PET/CT mainly facilitated biopsy, while diagnostic yield was more closely related to CRP and age. High comorbidity burden may contribute to diagnostic delay.